Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-04-30 11:41 am Purchase | 2026-03-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | VANGUARD CAPITAL MANAGEMENT LLC | 5,257,941 5.230% | 5,257,941 (New Position) | Filing History |
| 2026-03-27 10:50 am Sale | 2026-03-13 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | VANGUARD GROUP INC | 0 0.000% | -10,129,687 (Position Closed) | Filing History |
| 2026-01-21 08:13 am Purchase | 2025-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | JPMorgan Chase & Co. JPM | 5,198,084 5.200% | 5,198,084 (New Position) | Filing History |
| 2025-05-14 4:24 pm Purchase | 2025-03-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | Dodge & Cox | 5,534,624 5.600% | 5,534,624 (New Position) | Filing History |
| 2025-04-28 07:42 am Sale | 2025-03-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | BlackRock, Inc. BLK | 12,052,271 12.100% | -1,595,408 (-11.69%) | Filing History |
| 2025-03-06 2:09 pm Purchase | 2025-02-28 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | VANGUARD GROUP INC | 10,129,687 10.150% | 419,359 (+4.32%) | Filing History |
| 2025-02-05 06:50 am Sale | 2024-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | STATE STREET CORP STT | 4,891,137 4.800% | -257,156 (-4.99%) | Filing History |
| 2024-10-17 09:54 am Purchase | 2024-09-30 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | STATE STREET CORP STT | 5,148,293 5.100% | 5,148,293 (New Position) | Filing History |
| 2024-02-13 5:09 pm Purchase | 2023-12-29 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | VANGUARD GROUP INC | 9,710,328 9.880% | 370,033 (+3.96%) | Filing History |
| 2024-01-23 11:52 am Purchase | 2023-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | BlackRock, Inc. BLK | 13,647,679 13.900% | 1,020,276 (+8.08%) | Filing History |
| 2023-02-24 06:15 am Purchase | 2023-02-23 | 13D | VOYAGER THERAPEUTICS INC VYGR | NEUROCRINE BIOSCIENCES INC NBIX | 8,575,316 19.900% | 4,395,588 (+105.16%) | Filing History |
| 2023-02-09 11:27 am Purchase | 2022-12-30 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | VANGUARD GROUP INC | 9,340,295 9.720% | 552,304 (+6.28%) | Filing History |
| 2023-02-09 11:05 am Sale | 2022-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | JANUS HENDERSON GROUP PLC JHG | 2,415,638 2.500% | -5,030,201 (-67.56%) | Filing History |
| 2023-01-23 3:52 pm Purchase | 2022-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | BlackRock, Inc. BLK | 12,627,403 13.100% | 1,150,858 (+10.03%) | Filing History |
| 2022-02-14 2:34 pm Sale | 2021-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | T. Rowe Price Associates, Inc. | 4,359,645 4.500% | -1,912,085 (-30.49%) | Filing History |
| 2022-02-10 4:46 pm Sale | 2021-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | JANUS HENDERSON GROUP PLC JHG | 7,445,839 7.800% | -1,998,282 (-21.16%) | Filing History |
| 2022-02-10 08:27 am Purchase | 2021-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | VANGUARD GROUP INC | 8,787,991 9.260% | 450,726 (+5.41%) | Filing History |
| 2022-01-27 1:59 pm Unchanged | 2021-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | BlackRock, Inc. BLK | 11,476,545 12.100% | 0 (Unchanged) | Filing History |
| 2022-01-25 6:45 pm Purchase | 2021-12-31 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | BlackRock, Inc. BLK | 11,476,545 12.100% | 486,899 (+4.43%) | Filing History |
| 2021-08-10 10:33 am Sale | 2021-08-09 | 13G | NEUROCRINE BIOSCIENCES INC NBIX | FMR LLC | 3,780,076 3.994% | -4,656,553 (-55.19%) | Filing History |